Close Menu

NEW YORK – As the scope of the SARS-CoV-2 outbreak became apparent early this year, clinical labs across the US scrambled to develop and implement molecular tests for the virus.

The effort presented labs with a number of challenges, ranging from difficulties obtaining reagents and other materials needed for test development to the complexities of navigating unfamiliar regulatory regimes.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.